262 related articles for article (PubMed ID: 12198609)
21. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
Gilbert C; LeBlanc MH; Boivin G
Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
[TBL] [Abstract][Full Text] [Related]
22. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.
Le Page AK; Jager MM; Iwasenko JM; Scott GM; Alain S; Rawlinson WD
Clin Infect Dis; 2013 Apr; 56(7):1018-29. PubMed ID: 23243176
[TBL] [Abstract][Full Text] [Related]
23. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
24. Development of SYBR Green I-based real-time PCR assay for detection of drug resistance mutations in cytomegalovirus.
Liu JB; Zhang Z
J Virol Methods; 2008 Apr; 149(1):129-35. PubMed ID: 18280587
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
26. Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
Limaye AP
Clin Infect Dis; 2002 Oct; 35(7):866-72. PubMed ID: 12228824
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
28. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
[TBL] [Abstract][Full Text] [Related]
29. [Strains of ganciclovir-resistant cytomegalovirus].
Calicó I; García E; Cortés A; Gavaldá J; Roman A; Valle I
Enferm Infecc Microbiol Clin; 1999; 17(7):330-4. PubMed ID: 10535184
[TBL] [Abstract][Full Text] [Related]
30. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
31. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient.
Miller GG; Boivin G; Dummer JS; McConnell T; Becher MW; Kassim A; Tang YW
Clin Infect Dis; 2006 Feb; 42(4):e26-9. PubMed ID: 16421783
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
34. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
Baldanti F; Gerna G
J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
[TBL] [Abstract][Full Text] [Related]
35. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.
Choi SH; Hwang JY; Park KS; Kim Y; Lee SH; Yoo KH; Kang ES; Ahn JH; Sung KW; Koo HH; Kim YJ
Transpl Infect Dis; 2014 Dec; 16(6):919-29. PubMed ID: 25405808
[TBL] [Abstract][Full Text] [Related]
36. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
Chou S; Waldemer RH; Senters AE; Michels KS; Kemble GW; Miner RC; Drew WL
J Infect Dis; 2002 Jan; 185(2):162-9. PubMed ID: 11807689
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of human cytomegalovirus UL97 D605E mutation in transplant recipients in China.
Zhou L; Fan J; Zheng SS; Ma WH
Transplant Proc; 2006 Nov; 38(9):2926-8. PubMed ID: 17112867
[TBL] [Abstract][Full Text] [Related]
39. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
[TBL] [Abstract][Full Text] [Related]
40. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
Mousavi-Jazi M; Hökeberg I; Schloss L; Zweygberg-Wirgart B; Grillner L; Linde A; Brytting M
Transpl Infect Dis; 2001 Dec; 3(4):195-202. PubMed ID: 11844151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
